continu
threat
highli
pathogen
avian
influenza
viru
caus
futur
influenza
pandem
studi
screen
librari
compound
biolog
activ
structur
divers
inhibitori
activ
influenza
neuraminidas
na
found
aurintricarboxyl
acid
ata
potent
inhibitor
na
activ
influenza
virus
ic
effect
concentr
inhibit
na
activ
valu
low
micromolar
concentr
ata
equal
potent
inhibit
na
activ
deriv
wildtyp
na
mutant
render
na
resist
inhibit
oseltamivir
although
ata
structur
distinct
sialic
acid
molecular
model
experi
suggest
ata
bind
na
enzym
substrat
bind
site
result
indic
ata
may
good
start
materi
design
novel
class
na
inhibitor
treatment
influenza
virus
influenza
viru
caus
sever
epidem
respiratori
ill
year
recent
year
frequent
outbreak
subtyp
avian
influenza
infect
human
caus
seriou
concern
chang
et
al
although
vaccin
consid
first
line
defens
current
strategi
vaccin
design
manufactur
may
suffici
combat
influenza
pandem
neuraminidas
na
inhibitor
nai
effect
therapeut
agent
influenza
virus
target
viral
na
protein
von
itzstein
et
al
li
et
al
moscona
advent
zanamivir
relenza
oseltamivir
tamiflu
clearli
establish
na
valid
drug
target
develop
antiinfluenza
therapeut
klumpp
grave
garman
laver
although
agent
effect
prophylact
treatment
influenza
viru
infect
altern
treatment
need
drugresist
strain
alreadi
emerg
patient
receiv
oseltamivir
treatment
de
jong
et
al
carr
et
al
gubareva
et
al
monto
et
al
influenza
viru
na
essenti
viru
replic
facilit
releas
progeni
virion
infect
cell
seto
rott
pales
et
al
na
also
import
traffick
viru
mucu
layer
respiratori
tract
virus
get
access
underli
epitheli
cell
klenk
rott
na
present
surfac
viral
envelop
compos
tetram
ident
glycosyl
subunit
xray
crystallograph
studi
reveal
structur
head
tetramer
na
na
influenza
virus
classifi
two
genet
distinct
group
includ
subtyp
use
structurebas
drug
design
von
itzstein
et
al
includ
subtyp
strain
structur
avian
influenza
na
recent
solv
suggest
new
opportun
drug
design
discoveri
novel
caviti
adjac
activ
site
would
close
upon
substrat
bind
russel
et
al
studi
screen
compound
librari
inhibit
na
activ
deriv
influenza
viru
identifi
aurintricarboxyl
acid
ata
candid
inhibitor
ata
previous
shown
interfer
varieti
cellular
process
describ
gener
inhibitor
nucleas
hallick
et
al
ata
also
shown
protect
variou
cell
type
apoptot
cell
death
induc
varieti
factor
robertslewi
et
al
benchokroun
et
al
andrew
et
al
tsi
et
al
marchisio
et
al
also
report
indic
ata
could
inhibit
variou
type
kinas
involv
cellular
singal
pathway
eg
kappa
b
kinas
ikk
extracellular
signalregul
kinas
erk
tsi
et
al
myskiw
et
al
ata
also
shown
inhibit
cytokineinduc
jakstat
signal
pathway
ata
describ
insulinlik
growth
factor
igfi
mimet
could
promot
prolifer
cell
serumfre
cultur
medium
presum
activ
insulinlik
growth
factor
signal
pathway
beeri
et
al
addit
aforement
cellular
process
ata
may
interf
ata
also
report
inhibit
replic
differ
kind
virus
includ
human
immunodefici
viru
hiv
schol
et
al
sarscov
yap
et
al
et
al
vaccinia
viru
myskiw
et
al
etc
studi
discov
ata
also
inhibit
function
na
encod
influenza
virus
also
found
ata
equal
effect
inhibit
wildtyp
na
oseltamivirresist
na
mutat
na
de
jong
et
al
molecular
model
experi
indic
ata
bind
bind
site
substrat
test
compound
mainli
spectrum
collect
microsourc
discoveri
system
inc
gaylordsvil
ct
usa
contain
biolog
activ
structur
divers
compound
addit
sever
inhous
collect
compound
includ
ata
also
includ
screen
na
inhibitor
ata
purchas
sigmaaldrich
st
loui
mo
usa
dissolv
dimethyl
sulfoxid
dmso
mm
stock
stock
solut
store
c
oseltamivir
carboxyl
synthes
dr
ks
shia
nation
health
research
institut
nhri
taiwan
chemiluminesc
substrat
sodium
tricycl
decan
onat
na
releas
product
util
na
highthroughput
screen
assay
indic
nastar
kit
appli
biosystem
foster
citi
ca
usa
fluorogen
substrat
acid
munana
product
util
na
assay
obtain
sigmaaldrich
influenza
strain
shih
et
al
influenza
viru
reassort
strain
wood
robertson
util
studi
madindarbi
canin
kidney
mdck
cell
obtain
american
type
cultur
collect
manassa
va
usa
maintain
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
dmem
contain
gml
tpck
tolylsulfonyl
phenylalanyl
chloromethyl
keton
trypsin
use
infect
medium
mdck
cell
pgemt
easi
plasmid
promega
madison
wi
usa
bear
na
gene
fragment
influenza
viru
strain
use
target
sitedirect
pcr
mutagenesi
na
gener
sitespecif
mutat
two
primer
set
design
wsn
aat
tct
tac
tac
gag
gaa
tgt
tcc
tgt
wsn
ctc
gta
gta
aga
att
agg
tgc
att
caa
vn
aat
tat
gcc
tat
gag
gaa
tgc
tcc
tgt
vn
ctc
ata
ggc
ata
att
agg
atc
caa
mutat
site
creat
pcr
use
mm
dntp
primer
ng
templat
dna
appropri
amount
turbo
pfu
dna
polymeras
buffer
stratagen
la
jolla
ca
usa
thermal
cycl
profil
c
min
follow
cycl
c
c
min
c
min
final
extens
c
min
pcr
amplif
dpni
ad
digest
plasmid
templat
amplifi
dpniinsensit
mutat
plasmid
introduc
e
coli
select
design
mutant
sequenc
na
gene
strain
obtain
fodor
et
al
pcr
primer
carri
site
ecori
xhoi
ccg
ctc
gag
cgg
cgc
cac
cat
gaa
tcc
aaa
cca
gaa
ccg
gaa
ttc
cgg
cta
ctt
gtc
aat
ggt
gaa
cgg
c
subtyp
na
gene
retriev
cdna
librari
establish
revers
transcript
primer
agc
aaa
agc
follow
pcr
amplif
primer
pcramplifi
na
insert
clone
pgemt
easi
vector
promega
na
gene
cut
pgemt
plasmid
digest
ecori
xhoi
restrict
enzym
ecorixhoi
fragment
introduc
modifi
transfer
vector
clontech
palo
alto
ca
usa
carri
enhanc
green
fluoresc
protein
gene
weak
metallothionein
promot
select
marker
construct
cotransfect
linear
viral
dna
insect
cell
system
success
homolog
recombin
produc
infecti
baculoviru
express
na
protein
select
singl
clone
recombin
baculovirus
cultur
medium
baculovirusinfect
insect
cell
cultur
harvest
serial
dilut
infect
cell
plate
subsequ
select
viru
clone
amplifi
plate
cultur
media
infect
cell
collect
store
viru
stock
product
na
util
na
enzymat
assay
recombin
baculovirus
ie
bacna
wt
wsn
bacna
wsn
bacna
wt
bacna
gener
express
wildtyp
mutant
na
origin
influenza
although
exactli
locat
na
wt
wsn
na
wt
phe
point
mutat
refer
studi
util
literatur
design
specif
amino
acid
chang
respons
tamiflu
resist
et
al
abe
et
al
baz
et
al
largescal
influenza
viru
suspens
prepar
mdck
cell
infect
influenza
viru
inactiv
viral
infect
viru
suspens
treat
formaldehyd
final
concentr
c
min
demonstr
prepar
safe
handl
bench
viral
titer
detect
limit
without
decreas
na
activ
result
shown
aliquot
inactiv
viru
supernat
store
c
na
enzymat
activ
measur
use
fluorogen
substrat
munana
potier
et
al
na
activ
assay
conduct
plate
contain
l
dilut
viru
supernat
contain
activ
influenza
na
munana
substrat
per
well
buffer
mm
nmorpholino
ethanesulfon
acid
wood
robertson
mm
cacl
ph
compound
screen
evalu
inhibitori
activ
ata
inactiv
viru
supernat
preincub
test
compound
min
c
enzymat
reaction
carri
h
c
termin
l
stop
solut
ethanol
glycin
ph
fluoresc
intens
product
measur
use
fluoroskan
spectrofluoromet
labsystem
helsinki
finland
excit
emiss
wavelength
nm
respect
ic
reduc
na
activ
determin
free
use
gener
standard
curv
assess
na
activ
examin
initi
hit
compound
identifi
na
inhibit
assay
inhibit
cytopath
effect
cpe
cell
infect
influenza
virus
tissu
cultur
plate
seed
l
mdck
cellsml
dmem
fb
cell
incub
h
c
viru
multipl
infect
moi
per
cell
mix
differ
concentr
compound
ad
cell
h
viral
adsorpt
infect
cell
overlaid
l
dmem
dmso
incub
c
h
end
incub
cell
fix
l
formaldehyd
h
room
temperatur
remov
formaldehyd
cell
stain
crystal
violet
min
room
temperatur
plate
wash
dri
intens
crystal
violet
stain
well
measur
nm
concentr
requir
test
compound
reduc
cpe
viru
ic
determin
oseltamivir
carboxyl
use
refer
control
cpe
inhibit
test
cell
viabil
determin
mt
assay
cori
et
al
mdck
cell
grown
cellswel
plate
h
medium
replac
contain
serial
dilut
compound
cell
incub
h
cultur
medium
remov
ad
l
includ
mt
pm
mixtur
solut
plate
incub
min
mt
pm
purchas
sigma
prepar
pb
phosphatebuff
salin
identifi
microtit
plate
ml
reagent
contain
mt
pm
ratio
mix
immedi
ml
serumfre
dmem
drug
concentr
perform
four
repeat
optic
densiti
measur
nm
elisa
reader
plaqu
assay
use
determin
effect
ata
influenza
viru
replic
plaqu
assay
perform
describ
sidwel
smee
plate
contain
confluent
mdck
monolay
cell
use
refer
control
experi
cell
inocul
influenza
viru
titer
approxim
plaqu
form
unit
pfu
per
well
h
incub
c
infect
media
aspir
well
cover
ml
agar
overlay
media
contain
variou
concentr
compound
incub
day
c
co
incub
cell
fix
addit
ml
formaldehyd
h
room
temperatur
remov
formaldehyd
cell
stain
crystal
violet
min
room
temperatur
plate
wash
dri
number
plaqu
count
well
concentr
requir
ata
reduc
number
plaqu
ec
determin
vero
cell
infect
influenza
viru
moi
variou
concentr
compound
ad
cell
cultur
media
h
cultur
media
collect
subject
viru
titrat
plaqu
form
assay
describ
dock
ata
bind
site
avian
influenza
na
protein
russel
et
al
explor
use
gemdock
yang
chen
yang
shen
yang
et
al
gold
jone
et
al
softwar
shown
power
tool
molecular
recognit
virtual
screen
thomsen
christensen
knox
et
al
valid
molecular
model
program
first
evalu
dock
accuraci
gemdock
gold
dock
two
known
na
inhibitor
oseltamivir
carboxyl
zanamivir
bind
site
structur
ata
prepar
corina
sadowski
et
al
structur
zanamivir
extract
crystal
structur
na
pdb
code
russel
et
al
na
pdb
code
russel
et
al
respect
protein
data
bank
pdb
bind
pocket
call
na
avian
influenza
na
pdb
code
russel
et
al
defin
includ
amino
acid
residu
within
radiu
sphere
center
around
bind
site
coordin
atom
bind
pocket
obtain
pdb
microsourc
spectrum
collect
compound
sever
inhous
collect
compound
test
inhibit
na
activ
use
chemiluminesc
nastar
assay
kit
assay
decreas
chemiluminesc
would
indic
inhibit
releas
enzymat
hydrolysi
nastar
mediat
na
inactiv
viral
suspens
influenza
compound
test
na
activ
assay
employ
posit
control
screen
assay
na
deriv
strain
until
initi
hit
includ
ata
display
inhibit
chemiluminesc
signal
tabl
sinc
wish
discov
compound
activ
inhibit
influenza
viru
replic
initi
hit
na
inhibit
assay
subject
cpe
inhibit
assay
ata
periplocymarin
two
compound
could
inhibit
cpe
without
caus
appar
cytotox
tabl
ic
ata
cpe
inhibit
assay
select
index
cc
ic
ata
approxim
analysi
reveal
ata
inhibit
influenza
viru
na
dosedepend
manner
fig
ic
valu
ata
na
inactiv
viral
suspens
influenza
use
fluorogen
substratemunana
respect
thu
ata
potent
inhibitor
human
influenza
viru
na
na
russel
et
al
control
experi
determin
ata
mm
interfer
fluoresc
emiss
enzymat
product
na
reaction
data
shown
thu
ata
inde
inhibit
namedi
hydrolysi
munana
ic
less
nm
kind
influenza
virus
test
shown
effect
ata
influenza
viru
replic
evalu
use
plaqu
reduct
yield
reduct
assay
ata
variou
concentr
evalu
viru
plaqu
reduct
assay
influenza
reassort
ata
dosedepend
manner
reduc
plaqu
format
unit
pfu
caus
infect
mdck
cell
differ
strain
influenza
viru
fig
ec
valu
viral
plaqu
format
estim
influenza
evalu
effect
ata
yield
progeni
viru
assay
variou
concentr
ata
ad
infect
mdck
cell
influenza
moi
h
postinfect
cultur
supernat
collect
viru
yield
determin
plaqu
form
assay
shown
fig
ata
seem
margin
activ
reduc
yield
influenza
progeni
viru
infect
cell
howev
ata
exhibit
strong
antivir
activ
reduc
viral
yield
fold
refer
control
effect
reduc
viral
yield
cell
treat
fig
lower
concentr
reduct
yield
progeni
viru
could
observ
interest
examin
whether
ata
also
effect
inhibit
oseltamivirresist
na
due
mutat
na
wang
et
al
safeti
reason
intend
avoid
gener
manipul
drugresist
influenza
viru
mutant
therefor
insect
cell
protein
express
technolog
employ
express
sever
variant
na
studi
sensit
ata
cell
lysat
cell
cultur
supernat
insect
cell
infect
bacna
wt
wsn
bacna
wsn
bacna
wt
bacna
na
activ
data
shown
cell
cultur
supernat
also
contain
substanti
na
activ
may
due
fact
na
like
embed
envelop
bud
baculoviru
particl
suggest
mather
et
al
sensit
na
variant
ata
test
use
cell
lysat
prepar
insect
cell
infect
baculovirus
assay
mutat
na
subtyp
ie
na
wsn
na
result
resist
oseltamivir
carboxyl
activ
ingredi
oseltamivir
mendel
abe
et
al
ic
valu
ata
inhibit
na
activ
estim
na
wt
wsn
na
wsn
na
wt
na
respect
fig
thu
ata
remain
equal
potent
inhibit
activ
mutant
form
wildtyp
na
deriv
either
influenza
subtyp
gemdock
gold
employ
predict
dock
conform
ata
zanamivir
respect
bind
caviti
na
base
calcul
bind
energi
fig
show
dock
conform
two
known
compound
zanamivir
lowest
score
valu
compar
crystal
structur
base
rootmeansquar
deviat
rmsd
heavi
atom
averag
rmsd
gemdock
gold
less
zanamivir
respect
thu
deriv
gemdock
gold
paramet
adapt
predict
dock
conform
ata
bind
site
dock
conform
fig
hydrogen
bond
network
ata
slightli
differ
fig
dock
conform
aurintricarboxyl
acid
ata
green
gray
zanamivir
blue
avian
influenza
neuraminidas
dock
conform
ata
obtain
use
gemdock
bind
pocket
neuraminidas
deriv
protein
data
bank
pdb
code
main
contact
residu
yellow
neuraminidas
label
hydrogen
bond
dash
green
line
ata
green
neuraminidas
indic
interpret
refer
color
figur
legend
reader
refer
web
version
articl
zanamivir
analyz
bind
mechan
ata
na
divid
bind
site
na
sever
subsit
stoll
et
al
kati
et
al
zanamivir
inhibit
na
mimick
electrostat
hydrogen
bond
interact
substrat
bind
three
subsit
hydrophob
interact
subsit
kim
et
al
conform
analysi
indic
subsit
ata
form
hydrogen
bond
network
highli
conserv
known
nai
stoll
et
al
kati
et
al
russel
et
al
tabl
ata
also
form
hydrogen
bond
guanidin
group
form
hydrogen
bond
zanamivir
vitro
select
studi
demonstr
mutat
common
substitut
group
na
resist
oseltamivir
resist
result
partial
loss
hydrogen
bond
carboxyl
group
oseltamivir
mutat
would
littl
effect
group
na
carboxyl
group
form
addit
hydrogen
bond
russel
et
al
result
gemdock
gold
suggest
ata
interact
subsit
side
chain
backbon
oxygen
subsit
carboxyl
group
backbon
oxygen
sever
hydrogen
bond
interact
fig
tabl
addit
carboxyl
group
ata
appear
form
new
hydrogen
bond
nitrogen
atom
bident
hydrogen
bond
donoracceptor
mode
hand
known
nai
zanamivir
util
amino
group
form
strong
chargecharg
type
hydrogen
bond
interact
kim
et
al
acid
group
ata
steric
interact
hydrocarbon
chain
constitut
hydrophob
pocket
relat
inhibit
na
ata
russel
et
al
kim
et
al
amino
acid
residu
mutat
influenza
strain
posit
pocket
russel
et
al
le
et
al
mutat
could
perturb
rearrang
space
lead
increas
resist
varghes
et
al
yen
et
al
wang
et
al
upon
comparison
orient
substitut
group
ata
pocket
observ
ata
bind
allow
rearrang
space
urgent
need
new
antiinfluenza
therapeut
object
studi
identifi
novel
na
inhibitor
whose
chemic
structur
distinct
sialic
acid
screen
approxim
structur
divers
compound
found
ata
potent
inhibitori
activ
na
ata
previous
found
inhibit
influenza
viru
replic
mechan
action
attribut
inhibit
influenza
viral
polymeras
activ
ata
steward
et
al
liao
et
al
previou
studi
ata
shown
inhibit
viral
polymeras
vitro
assay
use
purifi
influenza
viru
protein
howev
test
inhibitori
activ
ata
influenza
viral
polymeras
use
cellbas
assay
found
ata
inhibit
influenza
polymeras
assay
ad
ata
human
embryon
kidney
cell
coexpress
influenza
polymeras
complex
protein
includ
pa
np
along
report
plasmid
ppolicatrt
report
plasmid
ppolicatrt
contain
vrnalik
rna
encod
report
gene
chloramphenicol
acetyltransferas
cat
neg
sens
flank
noncod
region
ns
vrna
segment
influenza
viru
pleschka
et
al
surpris
ata
inhibit
rnadepend
rna
polymeras
rdrp
deriv
express
cat
concentr
shown
concentr
viral
plaqu
format
clearli
inhibit
fig
base
cellbas
rdrp
assay
conclud
polymeras
influenza
may
primari
molecular
target
ata
find
reminisc
previou
studi
inhibitori
effect
ata
ata
found
inhibit
hiv
replic
mechan
propos
inhibit
viral
revers
transcriptas
rt
balzarini
et
al
howev
later
result
indic
ata
inhibit
hiv
replic
primarili
bind
viru
receptor
cell
surfac
schol
et
al
de
clercq
addit
influenza
viru
hiv
ata
recent
report
inhibit
virus
sarscov
vaccinia
viru
et
al
myskiw
et
al
ata
strong
inhibitor
influenza
viru
compar
antisarscov
activ
ec
ata
sarscov
mgml
et
al
wherea
ec
ata
influenza
viru
studi
low
rang
interest
note
ec
ata
measur
plaqu
reduct
assay
ic
measur
na
inhibit
assay
order
magnitud
howev
ic
ec
less
nm
nm
respect
influenza
reassort
inasmuch
ata
also
pleiotrop
effect
cellular
function
hallick
et
al
robertslewi
et
al
benchokroun
et
al
andrew
et
al
tsi
et
al
marchisio
et
al
myskiw
et
al
chen
et
al
beeri
et
al
na
may
sole
target
ata
interfer
exert
strong
antivir
action
find
congruent
recent
report
indic
ata
inhibit
replic
vaccinia
viru
target
cellular
viral
factor
myskiw
et
al
final
molecular
model
experi
predict
ata
bind
substrat
bind
site
na
molecular
model
experi
appli
examin
dock
ata
monomer
dimer
trimer
from
sinc
ata
known
present
multimer
form
cushman
et
al
b
dock
conform
ata
monom
ata
dimer
ata
trimer
ata
polym
use
gemdock
distinct
result
shown
found
ata
dimer
ata
trimer
lost
import
hydrogen
bond
interact
present
upon
bind
ata
monom
zanamivir
na
tabl
ata
polym
consist
three
ata
dock
pocket
observ
impli
ata
monom
might
best
form
inhibit
activ
na
among
ata
monomer
polymer
form
warrant
examin
exact
bind
mode
ata
na
crystallograph
studi
understand
exact
bind
mode
ata
na
would
shed
light
design
novel
class
nai
combat
influenza
viru
infect
find
ata
novel
nai
shall
prove
import
design
secondgener
nai
block
replic
influenza
virus
resist
oseltamivir
treatment
